PRESS RELEASE

26th November, 2019, Vadodara, India

Alembic Pharmaceuticals receives USFDA Final Approval for Silodosin Capsules, 4 mg and 8 mg.

Alembic Pharmaceuticals Limited today announced that the Company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Silodosin Capsules, 4 mg and 8 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rapaflo Capsules, 4 mg and 8 mg, of Allergan Sales, LLC. Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Silodosin Capsules have an estimated market size of US$ 114 million for twelve months ending June 2019 according to IQVIA.

Alembic now has a total of 108 ANDA approvals (96 final approvals and 12 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at http://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 - 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 - 3007630 Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED VADODARA 390 003